• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Dossier.org

Market Intelligence

  • Sponsored Post
  • Market Dossier
  • Domain Dossier
  • About
  • Contact

Inflazome IP Portfolio Strengthened with Patents Granted in US and Europe

January 13, 2020 By admin Leave a Comment

Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple small molecule drugs that block harmful inflammation, today announces that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020.

The patents provide for compounds which have advantageous properties and show useful activity in the inhibition of NLRP3 inflammasome activation. Such compounds are useful in the treatment of a wide range of disorders, including Parkinson’s, Alzheimer’s and Motor Neuron Disease, in which inflammation arising from the NLRP3 inflammasome is implicated as a key factor. Inflazome currently has two ongoing Phase I studies with Inzomelid and Somalix.

These new patents strengthen Inflazome’s intellectual property portfolio that extends to 43 patent families, reinforcing the company’s leading innovative position in discovering targeted therapies for inflammatory-driven diseases.

Matt Cooper, Chief Executive Officer of Inflazome, commented: “The granting of these pioneering patents marks another milestone for Inflazome and strengthens our IP portfolio. The patents granted in the US and Europe cover our lead clinical candidate, Inzomelid. Both Inzomelid and our second drug, Somalix, are in the final stages of Phase I safety and tolerability trials for inflammatory diseases. We look forward to driving these drugs into further trials to help people with debilitating diseases.”

The patent was originally filed by the University of Queensland and Trinity College Dublin following a highly productive collaboration between Inflazome founders, Professor Matt Cooper (University of Queensland) and Professor Luke O’Neill (Trinity College Dublin). It was licensed exclusively to Inflazome when the company was founded.

About Inflazome
Inflazome is a biotech company leading the development of orally available drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes. Inflammasomes are understood to drive many chronic inflammatory conditions, from Parkinson’s and Alzheimer’s to asthma, inflammatory bowel disease, chronic kidney disease, cardiovascular disease, arthritis and NASH. Inflazome has two ongoing Phase I studies, the first with Inzomelid which is under development as an orally available, brain-penetrant drug, and the second with Somalix which is under development as an orally available, peripherally-restricted drug to address clinical unmet needs in inflammatory conditions. Inflazome is headquartered in Dublin, Ireland, with offices in Cambridge, UK and Brisbane, Australia.

To learn more visit: inflazome.com

About the NLPR3 Inflammasome
Activated NLRP3 acts as a ‘danger sensor’ in the body to release the pro-inflammatory cytokines IL-1β, IL-18 and induce uncontrolled, lytic cell death (pyroptosis). These processes lead to chronic inflammation, and as such, NLRP3 has been implicated in a large number of diseases.

Related

Filed Under: Briefing Tagged With: Inflazome, IP Portfolio, NLPR3 Inflammasome, patent research

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Exclusive
  • Domain Aftermarkets
  • Opinion
  • OSINT
  • VPNW
  • Press Media Release
  • Analysis
  • Digital market
  • Calendarial

Featured Posts

  • Kathryn Ammon, George J. Mitchell Scholarship, Class of 2020
  • GovernmentCIO Names Jason Windsor Chief Health Information Officer
  • Maryland Tech Startup Transformania Taps Former Vocus Executive Daniel Levinson as Chief Executive Officer
  • Toucan Toco
  • Videojet Named 2018 Elite Award Winner in “Chicago’s Best and Brightest Companies to Work For®” Competition
  • Sidetrade and Solocal sign AI partnership deal
  • Elbit Systems of America – Night Vision to be Led by Erik Fox
  • European Semifinalist of SEED AWARD was Unveiled, Highlighting the Integration of Technology and Humanity
  • 2019 DevOps World | Jenkins World Award Winners Announced
  • Global Business Aviation Outlook forecasts up to 7,700 new business jet deliveries worth $251 billion from 2019 to 2028

RSS Market Research Domains

  • Metaverse Market Research: MetaverseMarketResearch.com Sold
  • Extended Meta Reality Learning : XMRL.org, domain name for sale
  • Technology Roadmap: TechnologyRoadmap.com, domain name for sale
  • ShoppingPoll.com, domain name for sale
  • SurveyPolling.com, domain name for sale
  • Technology Research: TechnologyResearch.org, domain name for sale
  • Opinion.org, domain name for sale
  • Analysis.org, domain name for sale
  • MarketScenario.com (Market Scenario), domain name for sale
  • Tech Market Research: TechMarketResearch.com, domain for sale

Copyright © 2013 Dossier.org

Technologies, Market Analysis & Market Research Reports

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT